Technology ID

Novel Rift Valley Fever Virus Vaccines

Linked ID
Brian Bird (CDC)
Cesar Albarino (CDC)
Stuart Nichol (CDC)
Thomas Ksiazek (CDC)
Lead Inventors
Brian Bird (CDC)
Cesar Albarino (CDC)
Stuart Nichol (CDC)
Thomas Ksiazek (CDC)
Development Stages
Pre-clinical (in vivo)
Development Status
  • In vitro data available
  • In vivo data available (animal)
Therapeutic Areas
Infectious Disease
Commercial Applications
  • Rift Valley fever (RVF) virus vaccine development or improvement
  • Prevention of RVF virus infection in livestock and humans
  • Biodefense, biosecurity
This invention relates to recombinant Rift Valley fever (RVF) viruses containing deletions in one or more virulence genes. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent RVF infection in livestock and humans. The recombinant RVF viruses grow to high titers, provide protective immunity following a single injection, and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus. Additionally, this technology relates to a method of using reverse genetics to generate recombinant RVF viruses.
Competitive Advantages
  • In vivo evidence shows single-dose protection
  • Allows for discrimination between vaccinated and naturally-infected subjects
  • Useful for controlled screening of therapeutic compounds

Request More Info

Licensing Contact